Skip to main content
REGN
NASDAQ Life Sciences

杜必欣（Dupixent）获得美国批准用于治疗幼儿慢性自发性荨麻疹

feedReported by GlobeNewswire
Sentiment info
Positive
Importance info
8
Price
$744.42
Mkt Cap
$78.915B
52W Low
$476.487
52W High
$821.11
Market data snapshot near publication time

summarizeSummary

美国FDA已批准杜必欣（dupilumab）用于治疗2至11岁的儿童，用于治疗无法控制的慢性自发性荨麻疹（CSU），使其成为该欠发达人群的首种生物制剂。继4月13日欧盟批准相同适应症后，这进一步扩大了雷根诺（Regeneron）畅销药的市场。该标签扩展是一个重大的积极发展，通过解决超过14,000名美国儿童的未满足的医疗需求，开辟新的收入来源，强化杜必欣在2型炎症性疾病中的增长轨迹和市场领导地位。

在该公告发布时，REGN的交易价格为$744.42，交易所为NASDAQ，所属行业为Life Sciences，市值约为$789.2亿。 52周交易区间为$476.49至$821.11。 这则新闻被评估为积极市场情绪，重要性评分为8/10。 来源：GlobeNewswire。

show_chartPrice Chart

Share this article

Copied!

feed REGN - Latest Insights

REGN
Apr 29, 2026, 6:54 AM EDT
Filing Type: 10-Q
Importance Score:
8
Regeneron Reports Mixed Q1 Results, Authorizes $3B Buyback, Details Government Pricing Deals & Key Legal Updates
Sentiment: Neutral
View Wiseek Article
REGN
Apr 29, 2026, 6:50 AM EDT
Filing Type: 8-K
Importance Score:
8
Regeneron Reports Strong Q1 Results, Authorizes New $3.0 Billion Share Repurchase, and Secures Strategic Government Pricing Agreement
Sentiment: Positive
View Wiseek Article
REGN
Apr 29, 2026, 6:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Regeneron Posts 19% Revenue Growth in Q1, Non-GAAP EPS Up 15% Amidst GAAP Decline
Sentiment: Positive
View Wiseek Article
REGN
Apr 24, 2026, 12:25 AM EDT
Source: dpa-AFX
Importance Score:
8
Regeneron's Otarmeni Gene Therapy Approved by FDA for Genetic Hearing Loss
Sentiment: Positive
View Wiseek Article
REGN
Apr 23, 2026, 12:42 PM EDT
Source: Reuters
Importance Score:
8
FDA Approves Regeneron's Gene Therapy for Inherited Deafness
Sentiment: Positive
View Wiseek Article
REGN
Apr 23, 2026, 1:30 AM EDT
Source: Reuters
Importance Score:
7
Dupixent Sales Soar 30.8%, Beating Estimates in Sanofi's Q1 Report
Sentiment: Positive
View Wiseek Article
REGN
Apr 22, 2026, 5:30 PM EDT
Source: GlobeNewswire
Importance Score:
8
Dupixent Gains U.S. Approval for Young Children with Chronic Spontaneous Urticaria
Sentiment: Positive
View Wiseek Article
REGN
Apr 21, 2026, 10:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Regeneron's Cemdisiran Phase 3 Data Published, Regulatory Filing Submitted for gMG
Sentiment: Positive
View Wiseek Article
REGN
Apr 13, 2026, 1:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Dupixent Secures EU Approval for Young Children with Chronic Urticaria, Expanding Key Market
Sentiment: Positive
View Wiseek Article
REGN
Apr 12, 2026, 7:08 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Regeneron Forms Radiopharma Partnership with Telix, Potentially Worth Over $2.1 Billion
Sentiment: Positive
View Wiseek Article